the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.

NCT07396714 | Not Yet Recruiting Early Phase 1

• 1 other identifier: ivermectin for cutaneous warts
• Study Type: interventional
• Target: 88
• Locations: 0 countries
• Sites: N/A

Brief Summary

To compare between the efficacy and safety of topical ivermectin alone, microneedling with topical ivermectin and topical salicylic acid in treatment of cutaneous warts. topical ivermectin 1% will be applied on warts whole night clinical assessment will be done every 2 weeks Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of topical ivermectin 1% will be applied on to the wart tissue. Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)

Conditions

Warts

Keywords

topical ivermectin with microneedling in warts treatment

Outcome Measures

Primary Outcomes (1)

• evaluation of the efficacy of topical ivermectin in treatment of cutaneous warts.

  clinical assessment of warts at the baseline \& each visit comparing photographs at different timeline .

  baseline

Secondary Outcomes (1)

• evaluation of the efficacy of topical ivermectin combined with microneedling in treatment of cutaneous warts.

  baseline

Study Arms (4)

topical ivermectin

EXPERIMENTAL

Drug: Ivermectin

microneedling

EXPERIMENTAL

patients with cutaneous warts will be treated with microneedling.

Device: microneedling

microneedling with ivermectin

EXPERIMENTAL

patients with cutaneous warts will be treated with topical ivermectin with microneedling.

Drug: Ivermectin; Device: microneedling

topical salicylic acid

ACTIVE COMPARATOR

patients with cutaneous warts will be treated with topical salicylic acid.

Drug: Salicylic Acid

Interventions

Ivermectin DRUG

patients with non-genital cutaneous warts will be treated by topical application of ivermectin : topical ivermectin 1% will be applied under occlusion overnight daily then revaluated every 2 weeks for maximum 12 weeks

microneedling with ivermectin; topical ivermectin

microneedling DEVICE

patients with non-genital cutaneous warts will be treated by microneedling (2mm depth) every 2-weeks until complete clearance or for a maximum of 12weeks

microneedling; microneedling with ivermectin

Salicylic Acid DRUG

patients with non-genital cutaneous warts will be treated by topical application of ivermectin : cotton soaked with topical salicylic acid will be applied under occlusion overnight daily then revaluated every 2 weeks for maximum 12 weeks

topical salicylic acid

Eligibility Criteria

• Age: 11 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• patients with cutaneous non genital warts aged 11:80 y.
• No concurrent systemic or topical treatment of warts

You may not qualify if:

• Genital warts.
• Pregnancy and lactation.
• History of any bleeding, clotting disorder or using anticoagulants
• Chronic systemic diseases such as chronic renal failure, hepaticinsufficiency, and cardiovascular disorders.
• patients who received any treatment for warts in the last month before the study.
• Patients with history of neuropathy or peripheral ischemia.
• Patients with signs of inflammation or infection.
• Patients with history of a serious systemic or anaphylactic reaction or allergy to ivermectin.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Mehta N. Case study of oral ivermectin in patients with cutaneous warts. J Cardiovasc Dis Res. 2024;15(12):6438-46

  BACKGROUND

Related Links

• Related Info

MeSH Terms

Conditions

Warts

Interventions

Ivermectin; Percutaneous Collagen Induction; Salicylic Acid

Condition Hierarchy (Ancestors)

Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Macrolides; Polyketides; Lactones; Organic Chemicals; Complementary Therapies; Therapeutics; Physical Therapy Modalities; Punctures; Rehabilitation; Salicylates; Hydroxybenzoates; Benzoates; Acids, Carbocyclic; Carboxylic Acids; Hydroxy Acids; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Phenols

Study Officials

• Alaa mohamed ghazaly, MD

  Assiut University

  STUDY DIRECTOR

• Ayman Mohamed Mahran, MD

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

aya mohamed sayed, bechlor

CONTACT

01010556275; aya.m.abdelazia17@gmail.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: January 28, 2026
• First Posted: February 9, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): June 1, 2027
• Last Updated: February 9, 2026

Record last verified: 2026-01